Laurus Labs has announced a robust performance for the quarter ending in September, reporting a consolidated net profit of ₹436.74 crore. This figure represents a more than twofold increase compared to the same period in the previous fiscal year. The growth was primarily driven by a 33% rise in revenue from operations, which climbed to ₹2,206.37 crore, up from ₹1,653.47 crore reported in the corresponding quarter last year. Reflecting the company's strong financial position, the board has declared an interim dividend of ₹1 per equity share, based on a face value of ₹2 per share.
The company’s recent growth is largely attributed to the strong performance of its contract development and manufacturing organisation (CDMO) business, with significant contributions from the small molecules segment. Additionally, the Affordable Medicine division played a critical role in bolstering the overall revenue trajectory. Management noted that these results underscore the effectiveness of the company’s current operational strategy and the strength of its diversified portfolio.
In a move to further expand its research and development capabilities, Laurus Labs announced its acquisition of a 60% stake in Galenvs Sciences Inc., a contract research organisation headquartered in Montreal, Canada. The investment is valued at a pre-money valuation of $3.50 million. The company plans a total investment of $3.75 million, which involves a primary infusion of $2.75 million and a secondary acquisition of $1 million. Galenvs is recognised for its expertise in custom oligonucleotide synthesis and functional magnetic-nanoparticle technologies, which serve both diagnostics and therapeutics markets.
Simultaneously, the board has approved the acquisition of a 52% stake in the Hyderabad-based entity, SI & C Resins, at a pre-money valuation of ₹30 crore. Laurus Labs intends to invest a total of ₹32.50 crore in the company, which specialises in the production of high-quality polymer and silica-based products. These materials are essential to the chemical, pharmaceutical, and biotechnology sectors, aligning with Laurus's broader focus on technical expansion.
Founder and CEO Satyanarayana Chava attributed the quarterly success to the resilience of the firm's CDMO platform and its Affordable Medicines segment. Looking ahead, the company is actively executing a transformation strategy. A key milestone in this transition is the recent operationalisation of its first commercial-scale peptide plant located in Visakhapatnam. This facility is designed to meet the growing global demand for peptide therapeutics, an area where the company sees significant potential.
The company is also prioritising investments in specialised technologies, specifically within the realm of oligonucleotides and peptide-resins. By integrating these advanced manufacturing capabilities, Laurus Labs aims to position itself as a key supplier for complex pharmaceutical needs. These strategic moves represent a deliberate effort to diversify the company's technical output and address specific requirements in the global biotechnology landscape.
As the company moves into the next phase of its growth cycle, the market will likely monitor the integration of its new international and local assets. With the new peptide plant now functional and expansion plans involving Canadian research firms and domestic manufacturers underway, Laurus Labs is positioning itself for sustained operational relevance. The combination of strong quarterly earnings and these strategic acquisitions signals a period of active expansion for the pharmaceutical major.
Comments